Wang Chao, Li Ming, Wei Rong, Wu Junlong
Department of Orthopedic Surgery, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang 471009, China.
J Bone Oncol. 2020 Oct 16;25:100332. doi: 10.1016/j.jbo.2020.100332. eCollection 2020 Dec.
We sought to investigate the efficacy of adoptive transfer of TILs plus anti-PD1 therapy in metastatic osteosarcoma patients.
A total of 30 patients received anti-PD1 therapy (Group 1) while 30 patients were subjected to TILs plus anti-PD1 therapy (Group 2). Progression-free survival time (PFS) and overall survival time (OS) were analyzed using Kaplan-Meier analysis. Potential prognostic factors were analyzed using univariate and multivariate analyses.
The ORR in Group 2 is 33.3%, which is significantly higher than Group1 (6.67%). In addition, we found significantly prolonged mPFS (5.4 months) and mOS (15.2 months) in Group 2 compared to those in Group 1, which recorded mPFS and mOS of 3.8 and 6.6 months, respectively. Univariate and multivariate analyses indicate that patients with more infusions of TIL numbers and CD8TILs or less infusions of CD8 PD1TILs and CD4FoxP3 TILs show increased PFS and OS. Moreover, PD1 is another good prognostic factor that predict PFS and OS.
Overall, these findings indicated that TILs plus anti-PD1 therapy has significant clinical outcomes in metastatic osteosarcoma patients. However, further studies are essential to validate and characterize the therapeutic activity of TILs plus anti-PD1.
我们试图研究过继性转移肿瘤浸润淋巴细胞（TILs）联合抗程序性死亡蛋白1（PD1）疗法在转移性骨肉瘤患者中的疗效。
共有30例患者接受抗PD1治疗（第1组），而30例患者接受TILs联合抗PD1治疗（第2组）。采用Kaplan-Meier分析评估无进展生存期（PFS）和总生存期（OS）。使用单因素和多因素分析潜在的预后因素。
第2组的客观缓解率（ORR）为33.3%，显著高于第1组（6.67%）。此外，我们发现第2组的中位无进展生存期（mPFS，5.4个月）和中位总生存期（mOS，15.2个月）与第1组相比显著延长，第1组的mPFS和mOS分别为3.8个月和6.6个月。单因素和多因素分析表明，TIL数量和CD8+TILs输注次数较多或CD8+PD1+TILs和CD4+FoxP3+TILs输注次数较少的患者，其PFS和OS增加。此外，PD1是预测PFS和OS的另一个良好预后因素。
总体而言，这些结果表明TILs联合抗PD1疗法在转移性骨肉瘤患者中具有显著的临床疗效。然而，需要进一步研究来验证和表征TILs联合抗PD1的治疗活性。
